The myocardial and blood protective effects of ulinastatin combined with tranexamic acid in patients underwent valve replacement surgery with cardiopulmonary bypass.

OBJECTIVE:To study the combined ulinastatin and tranexamic acid on myocardium and cardiac valve replacement in patients with blood protective effect.METHODS:December 2010 to December 2011 cardiopulmonary bypass heart valve replacement surgery 80 patients were randomly divided into control group, UTI group, tranexamic acid group and UTI + tranexamic acid compound groups with 20 cases each. Record perioperative clinical characteristics, including intraoperative cardiac resuscitation, the CPB time, after a parallel time, the ascending aorta occlusion time, after high-dose inotropic number of cases of drug use, drainage, blood transfusion , mechanical ventilation time, ICU time, complications and hospital death. Detection at different time points blood platelet count, serum troponin I (cTnI), creatine kinase MB (CKMB) content.RESULTS:After four deaths in hospital complications occurred in 5 cases. Four patients died in hospital and the incidence of postoperative complications was no significant difference in mechanical ventilation time, ICU time was no significant difference between the postoperative hospital stay. Compared with the control group, the other groups of platelet count increased significantly (P0.05). After cardiopulmonary bypass surgery complex parallel time were significantly lower than the control group (P0.05), postoperative plasma CKMB, cTnI content, blood loss and blood transfusion were significantly decreased (P0.05).CONCLUSION:UTI composite tranexamic acid for heart valve replacement surgery on cardiac and blood has a good protective effect and promote postoperative recovery.